Latest News
See all →
ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium
Austin, Texas, October 25, 2025 - ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data…
Read more
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025
- Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups
Berlin, Germany,…
ITM to Announce Phase 3 COMPETE Trial Post Hoc Subgroup Analyses and Host Satellite Symposium at NANETS 2025
Garching / Munich, Germany, October 17, 2025 -ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced…
Read more
